author-photo

Torsten Haferlach

University of Münster

17

Papers

325

Citations

Citation Trend

Filter By

Papers (14) Sort By

Journal Conference Others

Color Atlas of Clinical Hematology: Molecular and Cellular Basis of Disease

2018
Show All
- Source
- Cite
- Save
Citations (0)
Autologous or allogeneic stem cell transplantation versus chemotherapy in acute myeloid leukemia and subgroups: A multicenter trial by the German AML Cooperative Group

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee

2015 Blood
Show All
- Source
- Cite
- Save
Citations (70)
lymphoma mutations are frequent and represent an early event in follicular EZH2

2013
Show All
- Source
- Cite
- Save
Citations (0)
AML with Translocation T(8;16) Shows Unique Cytomorphological, Cytogenetic, Molecular, and Prognostic Features and Therefore Qualifies as An Own Entity According to WHO Criteria.

2008 Blood
Show All
- Source
- Cite
- Save
Citations (0)
An Approach to Virtual Karyotyping for Unbalanced Rearrangements Based on Gene Expression Data.

2007 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Translocation t(14;19)(q32;q13) Is a Rare Abnormality in CLL and Associated with Trisomy 12, an Unmutated IgVH Status and a Distinct Gene Expression Profile.

2007 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Therapeutic outcome in prognostic subgroups of de-novo acute myeloid leukemia (AML) and the role of the age factor. A study in 1834 patients of 16 to 84 years

2005 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Biology Oriented Investigation of Treatment Strategies for Acute Myeloid Leukemia (AML): The AMLCG Approach

2003
Show All
- Source
- Cite
- Save
Citations (0)
6-Thioguanine, Cytarabine, and Daunorubicin (TAD) and High-Dose Cytarabine and Mitoxantrone (HAM) for Induction, TAD for Consolidation, and Either Prolonged Maintenance by Reduced Monthly TAD or TAD-HAM-TAD and One Course of Intensive Consolidation by Sequential HAM in Adult Patients at All Ages With De Novo Acute Myeloid Leukemia (AML): A Randomized Trial of the German AML Cooperative Group

2003 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (153)